Clinical Trial Update: 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients [Phase 3]

View source ↗

Summary

A 12-week open-label extension study of TNX-102 SL in patients with post-traumatic stress disorder was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• TNX-102 SL (cyclobenzaprine hydrochloride)

Snippet

Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: PTSD | Phase 3 | Status: TERMINATED | Results posted: 2025-02-06